Moderna’s experimental COVID-19 vaccine, which combines its initial shock with protection against the omicron variant, seems to be working, the company said Wednesday.
The creators of the COVID-19 vaccine are studying updated amplifiers they will offer in the fall to better protect people from future corovirus waves.
The results of a preliminary Moderna study showed that people who received a combined stroke experienced an eight-fold increase in anti-virus antibodies that could target the omcron mutant, the company said.
COVID-19 vaccines are now all based on the original version of the coronavirus. They still provide strong protection against serious illness, hospitalization, and death even after the super-contagious variant of omicron appears, especially if people have had a booster dose.
But the virus continues to mutate so quickly that it can bypass some vaccine protection and cause milder infections.
So U.S. regulators and the World Health Organization are considering whether to mandate a change in the vaccine prescription for a new phase of vaccine boosting in the fall, when the cold weather and back-to- school children are expecting further increase.
Key questions: How can we make this change without losing a strong defense against the worst consequences of COVID-19? And what is the right choice to aim for? After the huge growth of ohmmicrons in the winter, this genetically distinct mutant sibling is now a major threat, including one that raises the current wave of infections in the United States.
The Food and Drug Administration held a meeting in late June for its scientific advisors to discuss these questions and review data on potential new formulations from vaccine development trials. Pfizer is also studying a combination vaccine, which scientists call the bivalent vaccine.
Moderna said her new study showed that one month after the combined injection, recipients had higher levels of anti-omecro antibodies-and cross-protection from other earlier variants-than the original. and vaccines. However, antibodies naturally decrease, so it is not known how long the protection against infection will last.
The study was conducted on 437 people and safety is similar to today’s amplifiers, Moderna said. The findings were announced in a press release and have not been the subject of a scientific review.
Source: Huffpost
I’m Liza Grey, an experienced news writer and author at the Buna Times. I specialize in writing about economic issues, with a focus on uncovering stories that have a positive impact on society. With over seven years of experience in the news industry, I am highly knowledgeable about current events and the ways in which they affect our daily lives.